Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations
The use of prostate-specific antigen (PSA) testing for early detection of prostate cancer remains controversial. 1 In October 2011, the US Preventive Services Task Force (USPSTF) issued a recommendation against PSA screening for all men. 2 This change was associated with a decline in rates of PSA testing among men aged 50 to 74 years and a decline in cases of incident prostate cancer.
3,4 Given the evidence for heterogeneity in screening practices, 5 we sought to compare the use of PSA testing among urologists vs primary care physicians (PCPs) before and after the latest USP-STF guidelines, hypothesizing that the adoption of these recommendations would vary according to physician specialty.
Methods | We used the National Ambulatory Medical Care Survey to examine the use of PSA testing in 2010 (conducted between December 28, 2009 , and December 26, 2010 ) and 2012 (conducted between December 28, 2011 , and December 26, 2012 . The National Ambulatory Medical Care Survey is an annual, nationally representative survey of ambulatory care in the United States that collects information about outpatient physician visits, patient demographics, diagnoses, medications, and indications for consultation. Specialty of health care professionals was dichotomized as urologist and PCP (general and family practice and internal medicine). We examined the frequency of PSA testing according to specialty and year to evaluate the association between the 2012 USPSTF recommendations and changes in PSA testing among men aged 50 to 74 years. Heterogeneity in testing practices between physicians was modeled by assessing the interaction term of physician specialty × survey year within a logistic regression model estimating probability of PSA testing. Results were weighted to reflect the US population based on the complex survey design. A 2-tailed level of significance was set at P < .05. The Brigham and Women's Hospital Institutional Review Board waived approval for the study. Data analysis was conducted from July 21 to November 16, 2015.
Results | We included all visits for men aged 50 to 74 years (n = 1222) who presented to urologists (113 [9.2%]) or PCPs (1109 [90.8%]) for a preventive care visit. Men with a diagnosis of prostate cancer (n = 18), elevated PSA level (n = 1), benign prostatic hyperplasia (n = 31), prostatitis (n = 5), or other unspecified disorders of the prostate (n = 3) were excluded. This exclusion resulted in a weighted sample of 27 million eligible visits (unweighted n = 1164) in 2010 and 2012, of which 800 000 (un- 
Editor's Note

Use of Prostate-Specific Antigen Testing Is in the Eye of the Beholder
The use of prostate-specific antigen (PSA) screening for prostate cancer is controversial. Various organizations have released conflicting messages regarding the use of the PSA Odds ratios (ORs) demonstrate the association between year and odds of undergoing prostate-specific antigen (PSA) testing within each physician group. The interaction term of physician specialty × survey year assessed the heterogeneity of PSA testing practices. Complex samples logistic regression models adjusted for race/ethnicity, rectal examination at time of PSA test, significant physician characteristics, and patient comorbidities. PCP indicates primary care physician. Light blue line represents urologists; dark blue line, PCPs. The dashes provide a visual cue of the change in screening frequency following the new recommendations.
1
In this issue of JAMA Internal Medicine, Zavaski et al 2 report that since the release of the US Preventive Services Task Force statement, the rate of PSA testing has declined overall but still is performed more frequently for patients receiving PSA testing for preventive health reasons through their urologist rather than through their primary care physician. The vast majority of PSA testing is still performed by primary care physicians, but there seems to be a continued perception, more firmly held by urologists than by primary care physicians, that the screening is beneficial. Urologists may hold this belief because they have referred more men who request PSA testing or because they have seen more poor outcomes from metastatic prostate cancer. Regardless, recent data show some decline in the detection of early-stage prostate cancer, which likely reflects decreased ordering of PSA tests, and hopefully indicates avoidance of harms of cancer treatment, such as erectile dysfunction and urinary incontinence. 3 We will need to await data on rates of metastatic disease and prostate cancer deaths to understand the full effect of less PSA testing. To our knowledge, such data were not available 30 years ago when the PSA blood test became available. The American Urologic Association Quality Registry was developed in 2014 to better track prostate cancer care and should produce the type of information our patients deserve.
4
In the meantime, recommendations to reduce PSA screening will only strengthen with release of a Healthcare Effectiveness Data and Information Set measure 5 targeting the elimination of PSA screening in men older than 70 years. It is essential that, along with improved collection of outcomes data, we also have outcomes data on the myriad novel diagnostic and risk stratification tools rapidly becoming available, such as magnetic resonance imaging or ultrasound fusedguided prostate biopsy and genomic testing. Without such evidence, we can be sure that differing entrenched beliefs between urologists and primary care physicians will only become more expensive. Meanwhile, the widespread use of the PSA test should serve as a cautionary tale of the importance of first establishing that benefit exceeds harms before recommending new cancer screening tests.
